

**Neu-REFIX Beta 1,3-1,6 Glucans' beneficial effects in mice model of Duchenne Muscular Dystrophy; Lecture by Dr. Yoshitsugu Aoki in Japan Muscle Society Annual Meeting morning session, co-hosted by GN Corporation.**

Joint Conference of  
The 22nd Annual Meeting of Asian and Oceanian Myology Center and  
The 10th Annual Meeting of Japan Muscle Society

**MORNING SESSION:**  
**14, Sept. (Sat), 2024**  
**0800~0850 Japan time**

Jointly hosted by:  
GN Corporation Co Ltd, Kofu, Japan  
info@gncorporation.com

Speaker

Oral administration of  
Neu-REFIX Beta 1,3-1,6 Glucan  
reduces  
skeletal muscle fibrosis and fatigue  
in dystrophic mice

Moderator

  
**Dr. Yoshitsugu Aoki**  
Director, Dept of Molecular Therapy,  
National Center for Neurology & Psychiatry, Japan

  
**Prof. Masaru Iwasaki**  
Vice-President  
University of Yamanashi, Japan

For virtual participation, please scan the QR code and register:



\*For list of publications on pre-clinical and clinical studies, please visit [www.neurefix.com](http://www.neurefix.com)  
For Registration : <https://ncrmniche.org/AOMC-JMS-GNCsession/registration.html>

26, July, 2024. [Dr. Yoshitsugu Aoki, Director, Department of Molecular Therapy, National Center for Neurology and Psychiatry \(NCNP\)](#) will deliver a guest lecture on **“Oral administration of Neu-REFIX Beta 1,3-1,6 Glucans reduces skeletal muscle fibrosis and fatigue in dystrophic mice”** in the morning session of Joint Conference of **the 22<sup>nd</sup> Annual Meeting of Asian and Oceanian Myology Center and the 10<sup>th</sup> Annual Meeting of Japan Muscle Society** on the 14<sup>th</sup> September 2024, held in Nara, Japan. The session will be available for virtual listening for those who register [in the online portal](#). The presentation will be in English and will cover the research outcome in pre-clinical mdx mice models which simulate the disease pathology of Duchenne Muscular Dystrophy (DMD). The collaborative research studies were undertaken by the team of GN Corporation jointly with Dr. Aoki and his team of National Center of Neurology and Psychiatry (NCNP), Koidaira, Tokyo, Japan. Reduction in skeletal muscle fibrosis after Neu REFIX administration has been published in [Scientific reports](#) and the latest data on fore-limb grip of the mdx mice after Neu REFIX consumption were presented in the [MDA conference 2024](#).

[GN Corporation has been working to find a solution to the rare disease of Duchenne Muscular Dystrophy since 2009.](#) The safety proven orally consumable and allergen-free Neu REFIX Beta 1,3-1,6 Glucan which is produced as an exo-polysaccharide by Aureobasidium Pullulans in a GMP certified facility in Japan yielded anti-inflammatory and immune modulating potentials in [animal studies](#) and in [healthy volunteers](#) conducted in Japan. Based on the findings, the pre-clinical studies in mdx mice were conducted jointly with Dr Aoki, which he will present in the meeting.

Those who want to join the session may register with their email ID in the following website:  
<https://ncrmniche.org/AOMC-JMS-GNCsession/registration.html>

The recorded talk will also be broadcasted in the Duchenne Awareness Day 2024 webinar to be organized by JAICARE Hospital, Madurai, India on the 22<sup>nd</sup> September 2024, whose program is in the URL: <https://www.ncrmniche.org/duchenneawareness2024/index.html>.

#### CONTACT

[mail@medinippon.jp](mailto:mail@medinippon.jp)

(Medinippon Pvt.Ltd., is a sister concern of GN Corporation.Co.Ltd)